Comparative Pharmacology
Head-to-head clinical analysis: BILDYOS versus INVOKAMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BILDYOS versus INVOKAMET.
BILDYOS vs INVOKAMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BILDYOS (pemigatinib) is a selective, potent, oral inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, and 3. It binds to the ATP-binding pocket of FGFR kinases, inhibiting autophosphorylation and downstream signaling, thereby reducing proliferation and survival of tumor cells with FGFR alterations.
INVOKAMET is a combination of canagliflozin, an SGLT2 inhibitor, and metformin, a biguanide. Canagliflozin inhibits sodium-glucose cotransporter 2 in the renal proximal tubules, reducing glucose reabsorption and increasing urinary glucose excretion. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity.
Adults: 20 mg orally once daily.
Oral: Starting dose: 5 mg canagliflozin/500 mg metformin hydrochloride extended-release twice daily; titrate based on efficacy and tolerability, maximum 150 mg/1000 mg twice daily.
None Documented
None Documented
Approximately 24 hours at steady state; supports once-daily dosing.
Canagliflozin: 10–13 hours (multiple dosing); Metformin: 6.2 hours (plasma). Accumulation occurs in renal impairment.
Primarily biliary/fecal (unchanged drug and metabolites), approximately 90%; renal excretion accounts for less than 10% as unchanged drug and conjugates.
Canagliflozin (SGLT2 inhibitor): ~33% renal (1% unchanged, ~33% as glucuronide metabolites), ~52% fecal. Metformin (biguanide): 90% renal unchanged via tubular secretion.
Category C
Category C
SGLT2 Inhibitor/Biguanide Combination Antidiabetic
SGLT2 Inhibitor / Biguanide Combination